Zacks Investment Research
26 Jun 2026, 15:45 UTC · 1h ago
Nurix Therapeutics (NRIX) Soars 16.4%: Is Further Upside Left in the Stock?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
26 Jun 2026, 15:45 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Nurix Therapeutics (NRIX) entered an exclusive licensing and collaboration agreement with Roche to co-develop bexobrutideg (NX-5948). — A partnership with a global pharma giant like Roche provides critical validation and resources for a pipeline candidate.
+0.80Nurix Therapeutics is entitled to a $700 million upfront payment and potential total payments of up to $2.3 billion from Roche. — Significant non-dilutive funding drastically improves the company's balance sheet and runway for R&D.
+0.70Nurix Therapeutics is expected to report a quarterly revenue decline of 67.5% year-over-year to $14.3 million. — Significant revenue contraction is a negative fundamental signal, though often expected for early-stage biotech.
-0.30Continue reading
6 related stories
Top 1 mover · tap to explore
The consensus EPS estimate for Nurix Therapeutics has been revised 1.8% higher over the last 30 days. — Positive earnings revisions typically correlate with near-term upward price momentum.
+0.20Which stocks this story touches
Shares soared 16.4% following a high-value collaboration agreement with Roche.
Shares closed 4.7% lower in the last trading session and have returned -3.5% over the past month.
Entered into a strategic licensing and collaboration agreement to co-develop a lead pipeline candidate.
[mutual] Nurix Therapeutics and Roche signed an exclusive licensing and collaboration agreement to co-develop and co-commercialize bexobrutideg.
[mutual] Both companies are identified as belonging to the Zacks Medical - Biomedical and Genetics industry.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Zacks Investment Research
1h ago
